BioLineRx has announced that an Issue Notification has been received from the United States Patent and Trademark Office (USPTO) granting 1,787 days of Patent Term Adjustment for the patent claiming ...

BCM, also known as BL-1040, was in-licensed by Ikaria in 2009 from BioLineRx, which said it has spent about $10 million to develop it--but has made $17 million under the licensing deal. - here are ...

It now has about $83 million in cash to advance a pair of pipeline candidates it gleaned from its spinoff from Ikaria in October 2013. The IPO raised $60 million through the sale of 5 million ...

Seattle biotech Ikaria said Thursday it is acquiring INO Therapeutics in a merger that is valued at $670 million. As part of the deal, the ...

Mallinckrodt agreed to buy privately held Ikaria for about $2.3 billion, in a move to expand its presence in hospitals and in the area of critical care.